KYOTO-SEMICONDUCTOR
Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, announced its collaboration with Semtech Corporation (Nasdaq: SMTC ), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms. Kyoto Semiconductor has chosen to pair their new KP-A avalanche photodiode*1 , KPDEA13C with Semtech’s GN1089 transimpedance amplifier*2 to enable long distance optical communication.
"The pairing of Semtech’s transimpedance amplifier GN1089 with Kyoto Semiconductor’s KPDEA13C was ideal to optimize the performance,” said Tsuneo Takahashi, Kyoto Semiconductor president and CEO. “Through the joint collaboration, the KPDEA13C now includes a fast response suitable for a variety of optical needs.”
Kyoto Semiconductor’s KPDEA13C is front side illuminated, highly sensitive and mounted on an interposer board for ease of assembly. Additionally, Kyoto Semiconductor’s KPDEA13C and Semtech’s GN1089 together offer unparalleled performance at high speed enabling 25Gbaud PAM4*3*4 applications.
"Semtech’s GN1089 is a high performance transimpedance amplifier enabling both 25Gbaud and 56Gbaud applications. Its high linearity and low noise are features that were a perfect fit for the Kyoto Semiconductor, KPDEA13C,” said Timothy Vang, vice president, marketing and applications for Semtech’s Signal Integrity Products Group. “This collaboration with Kyoto Semiconductor showcases the outstanding quality of our solutions for high speed optical communications.”
Sample shipments of KP-A avalanche photodiode, KPDEA13C is scheduled to begin on August 31, 2021, and mass production is expected to start on December 27, 2021.
For evaluation report, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/news/2025/
- English: https://www.kyosemi.co.jp/en/news/1058/
For product datasheet, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/mgt/wp-content/uploads/2021/08/kpdea13c_jp.pdf
- English: https://www.kyosemi.co.jp/en/mgt/wp-content/uploads/2021/08/kpdea13c_en.pdf
For information on Semtech’s GN1089, please visit www.semtech.com/products/signal-integrity/transimpedance-amplifiers/gn1089
*1 Avalanche Photodiode
: Semiconductor Photodiode with photocurrent amplification by applying reverse bias voltage. This photocurrent amplification produces much more current than standard Photodiode. It is useful in the application where the high sensitivity is required.
*2 Transimpedance amplifier
: The circuit or device that convert a current from Photodiode to voltage.
*3 PAM4 (Pulse Amplitude Modulation 4-level)
: A technique of modulation. It uses four voltage levels to represent two bits logic, 00, 01, 10, and 11, against the traditional NRZ modulation uses two voltage levels to represents 1 bit logic, 0 and 1.
*4 25Gbaud PAM4
: PAM4 signal at 25Gbaud modulation speed. It achieves 2 times transmission speed compared with traditional 25Gbaud NRZ signal. i.e., 25Gbaud PAM4 achieves 50Gbps, against 25Gbaud NRZ achieves 25Gbps.
About Semtech’s Optical Products
Semtech’s optical networking product platforms provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure and passive optical network/Fiber to the X (FTTX) markets. For more information, visit https://www.semtech.com/products/signal-integrity
.
About Semtech
Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the NASDAQ Global Select Market under the symbol SMTC. For more information, visit http://www.semtech.com
.
About Kyoto Semiconductor
Kyoto Semiconductor was founded in Kyoto in 1980 as a specialized manufacturer of optical semiconductors. Based on our unique packaging technology, we manufacture semiconductors for optical communications and sensors, which boast high performance and high accuracy, at our own base in Japan with an integrated system from front-end to back-end processes, and supply them to customers around the world. Kyoto Semiconductor is a leader in optical device solutions with Japanese quality manufacturing, leveraging world-class technology. For more information, please. visit https://www.kyosemi.co.jp
.
*Semtech, the Semtech logo are registered trademarks or service marks of Semtech Corporation or its affiliates.
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication. Subject to change without notice. Please understand in advance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005473/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 11:15:00 CET | Press release
AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on Novem
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 07:16:00 CET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 07:00:00 CET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
